PDCD1 and non-small cell lung carcinoma: The ORR analysis which was done using fixed effects model due to very little heterogeneity between the different trials, except overall RR value of 1.53, (95% CI: 1.16-2.01, P = 0.003; I2 = 59.2%) in favor of PD-1/PD-L1 antibodies in NSCLC patients.